Effect of platelet-activating factor antagonist BN 52063 on the nephrotoxicity of cisplatin
Lipids - 1991
Tóm tắt
Cisplatin (DDP) is an effective anticancer agent that has been successfully applied against various solid tumors. However, DDP commonly causes nephrotoxicity. We observed that DDP led to significant alterations in renal microcirculation when administered to Munich-Wistar rats, with a concomitant decrease in single nephron glomerular filtration rate due to reduction in glomerular plasma flow and transcapillary hydraulic pressure difference. BN 52063, a platelet-activating factor antagonist, caused a striking change in acute renal failure induced by DDP leading toward normalization of all parameters of renal function. The results suggest that BN 52063 could be used as a novel drug to control DDP nephrotoxicity.
Từ khóa
Tài liệu tham khảo
Einhorn, L.H., and Williams, S.D. (1979)N. Eng. J. Med. 300, 289–291.
Yagoda, A., Watson, R., Gonzales, V.L., Grasstald, H., and Withmore, W. (1976)Cancer Treat. 60, 917–923.
Wittes, R.E., Cvitkovic, E., Shah, J., Gerold, F., and Strong, P. (1977)Cancer Treat. 61, 359–366.
Ries, F., and Katstersky, J. (1986)Am. J. Kid. Dis. 8, 368–379.
Winston, J.A., and Safirstein, R. (1985)Am. J. Physiol. 249, F490-F496.
Safirstein, R., Winston, J., Goldstein, M., Moel, D., Dikman, S., and Guttenplan, J. (1986)Am. J. Kid. Dis. 8, 356–367.
Schlondorff, D., and Neuwirt, R. (1986)Am. J. Physiol. 251, F1-F11.
DeBoer, D.K., Takahashi, D., Jacobson, H.R., and Badr, K.F. (1988)Kidney Int. 33, 260 (Abstract).
Santos, O.F.P., Boim, M.A., Bregman, R. Draibe, S.A., Barros, J.E.G., Pirotzky, E., Schor, N., and Braquet, P. (1989)Transplantation 47, 592–595.
Safirstein, R., Miller, P., and Dikman, S. (1981) inAcute Renal Failure (Eliahou, H.E., ed.), pp. 91–95, John Libbey, London.
Howell, S.B., and Taefle, R. (1980)Cancer Treat. Rep. 64, 611–616.
Schor, N., Ichikawa, I., and Brenner, B.M. (1981)Kidney Int. 20, 442–451.
Maddox, D.A., Price, D.C., and Rector, Jr., F.C. (1977)Am. J. Physiol. 233, F600-F606.
Viets, J.W., Deen, W.M., Troy, J.L., and Brenner, B.M. (1978)Anal. Biochem. 88, 513–521.
Deen, W.M., Robertson, C.R., and Brenner, B.M. (1972)Am. J. Physiol. 223, 1178–1183.
Vurek, G.G., and Pegram, S.E. (1966)Anal. Biochem. 16, 409–419.
Fuhr, J., Kaczmarczyk, J., and Kruttgen, C.D. (1955)Klin-Wochenschr. 33, 729–730.
Smith, H.W., Finkelstein, N., Aliminosa, L., Crawford, B., and Graber, M. (1945)J. Clin. Invest. 24, 388–404.
Clifton, G., Pearce, D., O'Neill, W.S., and Wallin, J.D. (1982)J. Lab. Clin. Med. 100, 659–670.
Safirstein, R., Miller, P., Dikman, S., Lyman, N., and Shapiro, C. (1981)Am. J. Physiol. 241, F175-F185.
Offerman, J.J.G., Meijer, S., Sleijfer, D.T., Mulder, N.H., Donker, A.J.M., Schraffordt-Koops, H., and van der Hem, G.K. (1984)Cancer Chemother. Pharmacol. 12, 36–39.
Offerman, J.J.G., Sleijfer, D.T., Mulder, N.H., Meijer, S., Schraffordt-Koops, H., and Donker, A.J.M. (1985)Cancer Chemother. Pharmacol. 14, 262–264.
Chopra, S., Kaufman, J.S., Jones, T.W., Hong, W.K., Gehr, M.K., Hamburger, R.J., Flamenbaun, W.S., and Trump, B.F. (1982)Kidney Int. 21, 54–64.
Daugaard, G., Abildgaard, U., Holstein-Rathtou, N.H., Amtorp, O., and Leyssac, P.P. (1987)Contrib. Nephrol. 56, 7–11.
McGiness, S.E., Proctor, P.H., Demopoulos, H.B., Hokanson, S.A. and Kikpatric, D.S. (1978)Physiol. Chem. Phys. 10, 367–377.
Caparro, G., Anastasia, P., Giordano, D., Alvarano, L., Rufolo, A., and De Santo, N.G. (1987)Adv. Exp. Med. Biol. 212, 285–290.